Raloxifene is a selective oestrogen receptor modulator. It has effects on bone and breast cancer and cardiovascular disease risk.

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

Methylamine occurs endogenously from amine catabolism and its tissue levels increase in some pathological conditions including diabetes.